Related Experiment Video
Updated: Jun 23, 2026

Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
Delayed recognition of intrathecal methotrexate overdose
Baris Malbora1, Emel Ozyurek, Aysu Inan Kocum
1Department of Pediatric Hematology, Baskent University Faculty of Medicine, Ankara, Turkey. barismalbora@gmail.com
Abstract:
A 10-year-old girl who presented to our hospital was diagnosed as having B-precursor cell acute lymphoblastic leukemia. St Jude's Total XIII protocol was started. In the second block of the consolidation phase, 10 hours after triple intrathecal treatment, we realized that instead of 12 mg, 120 mg of methotrexate had accidentally been given. Although the patient had no symptoms 10 hours after intrathecal treatment, to prevent the possible neurotoxic effects of methotrexate, a cerebrospinal fluid exchange was performed. Simultaneously, systemic dexamethasone and calcium folinic acid were given. At the time of this writing (2 y), the patient has had no symptoms and has continued on the chemotherapy protocol as planned. Administration of high-dose intrathecal methotrexate may not lead to symptoms, as was the case in our patient. This may be related to individual variations in cerebrospinal fluid dynamics and drug metabolism.
Related Concept Videos
Pharmaceutical Poisoning: Treatment Strategies
Drug toxicity: Idiosyncratic Reactions
Drug Toxicity: Dose-Dependent Reactions
Therapeutic Drug Monitoring: Affecting Factors
Drug Toxicity: Overview
Prevention of Further Absorption of Poison
